Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
Angela Moran(University of Oxford), Lauri Lehtimäki(Tampere University of Applied Sciences), Catherine Borg(University of Oxford), Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Simon Couillard(Université de Sherbrooke), Ian Pavord(Oxford BioMedica (United Kingdom)), Clare Connolly(University of Oxford), Christine Mwasuku(National Institute for Health and Care Research), Timothy Hinks(University of Oxford)
Cited by 76
Related Papers
Effectiveness and Safety of Bronchial Thermoplasty in the Treatment of Severe Asthma: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial
|American Journal of Respiratory and Critical Care Medicine|2009|686
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study
|The Lancet Respiratory Medicine|2015|584
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
|The Lancet|2021|310
Eosinophilic and Noneosinophilic Asthma
|CHEST Journal|2021|262